EyePoint Pharmaceuticals, Inc. (EYPT)
NASDAQ: EYPT · Real-Time Price · USD
5.05
-0.37 (-6.83%)
At close: Apr 1, 2025, 4:00 PM
5.28
+0.23 (4.53%)
After-hours: Apr 1, 2025, 4:26 PM EDT

Company Description

EyePoint Pharmaceuticals, Inc. engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases.

The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery.

Its lead product candidate is DURAVYU, an investigational sustained delivery treatment for VEGF-mediated retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor with Durasert E which is in Phase 3 clinical trials for wet age-related macular degeneration (wet AMD), non-proliferative diabetic retinopathy (NPDR), and diabetic macular edema (DME).

The company’s pipeline programs also include EYP-2301, a promising TIE-2 agonist formulated in Durasert E that is in pre-clinical development phase for potentially improve outcomes in serious retinal diseases.

The company was formerly known as pSivida Corp. and changed its name to EyePoint Pharmaceuticals, Inc. in March 2018.

EyePoint Pharmaceuticals, Inc. was incorporated in 1987 and is headquartered in Watertown, Massachusetts.

EyePoint Pharmaceuticals, Inc.
EyePoint Pharmaceuticals logo
Country United States
Founded 1987
IPO Date Jan 27, 2005
Industry Biotechnology
Sector Healthcare
Employees 165
CEO Jay Duker

Contact Details

Address:
480 Pleasant Street, Suite A-210
Watertown, Massachusetts 02472
United States
Phone 617 926 5000
Website eyepointpharma.com

Stock Details

Ticker Symbol EYPT
Exchange NASDAQ
Stock Type Common Stock
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001314102
CUSIP Number 30233G209
ISIN Number US30233G2093
Employer ID 26-2774444
SIC Code 3826

Key Executives

Name Position
Dr. Anna Kluczewska Chief Executive Officer of AION Diagnostics Ltd, President of AION Diagnostics Ltd and Director of AION Diagnostics Ltd
Dr. Jay S. Duker M.D. President, Chief Executive Officer and Director
George O. Elston CPA Executive Vice President and Chief Financial Officer
Ron I. Honig Esq. Chief Legal Officer and Company Secretary
Jennifer Leonard Chief People Officer and Senior Vice President of IT
David Scott Jones M.A. Senior Vice President and Chief Commercial Officer
Isabelle Lefebvre Chief Regulatory Officer
Michael J. Maciocio Chief Manufacturing Officer
Dr. Marcia Sellos-Moura Ph.D. Senior Vice President and Head of Development and Program Management
Dr. Ramiro Ribeiro M.D., Ph.D. Chief Medical Officer

Latest SEC Filings

Date Type Title
Mar 6, 2025 10-K Annual Report
Mar 5, 2025 8-K Current Report
Mar 4, 2025 8-K Current Report
Feb 14, 2025 SCHEDULE 13G/A Filing
Feb 12, 2025 SCHEDULE 13G/A Filing
Feb 5, 2025 8-K Current Report
Jan 27, 2025 SCHEDULE 13G/A Filing
Jan 13, 2025 8-K Current Report
Jan 8, 2025 8-K Current Report
Dec 4, 2024 8-K Current Report